ALMS (Alumis Inc.) — AI Stock Analysis & Recommendation

Research of September 10, 2026 · Healthcare / Pharmaceutical Preparations

TradeFlare's AI research teams rate ALMS a HOLD. The latest price is $7.13.

The research plan

• Entry: $9.90
• Target: $12.38
• Stop: $8.42
• Time horizon: weeks

The technicals are bearish and the risk profile is high, necessitating a cautious approach despite positive fundamental signals.

Why

The technicals are bearish and the risk profile is high, necessitating a cautious approach despite positive fundamental signals. Catalysts to watch: Progress towards NDA submission for envudeucitinib; Analyst 'strong_buy' consensus and high mean target price; Continued insider buying activity. Key risks: Recent Phase 2b trial miss for envudeucitinib in the overall lupus population; High realized volatility and significant 1-year drawdown; Bearish technical trend with price below key moving averages.

What could push ALMS higher

• Progress towards NDA submission for envudeucitinib.
• Analyst 'strong_buy' consensus and high mean target price.
• Continued insider buying activity.

Key risks for ALMS

• Recent Phase 2b trial miss for envudeucitinib in the overall lupus population.
• High realized volatility and significant 1-year drawdown.
• Bearish technical trend with price below key moving averages.

What each AI research team found

Fundamental team: Bullish · valuation: speculative

Alumis Inc. is a speculative, pre-revenue biopharmaceutical company with a strong fundamental outlook driven by its promising drug pipeline and significant analyst support. The current price is well below the mean analyst target, and while risks associated with clinical development and high cash burn exist, the potential for successful drug commercialization justifies a bullish stance with a medium-term outlook.

• Strong analyst consensus ('strong_buy') with a mean target price of $32.13, indicating significant upside potential from the current price.
• Alumis is a pre-revenue biopharmaceutical company with a substantial cash balance ($63.7M) and strong short-term liquidity (current ratio 6.74), providing runway for development.
• The company's lead drug candidate, envudeucitinib, is progressing towards an NDA submission, driving future revenue expectations.

Technical team: Bearish

The consensus among Trend, Momentum, and Pattern analysts points to a bearish outlook, supported by clear downtrend signals, bearish momentum indicators, and a bearish engulfing pattern. While volume is neutral, the confluence of other bearish signals and the current price being near resistance suggests a high probability of further downside towards the $7.58 support level.

• The price is in a clear downtrend, below key moving averages (MA20 and MA50), and approaching support, suggesting a bearish outlook with a target at $7.58.
• The stock is trading in a sideways range with low volume, suggesting a neutral outlook until a clear breakout or breakdown occurs.
• All indicators suggest a bearish trend, with price approaching the S2 support level, indicating a potential short entry.

Sentiment team: Neutral

ALMS sentiment is currently neutral, reflecting a tug-of-war between a significant Phase 2b trial miss and subsequent stock drop, countered by positive subgroup data, substantial insider buying, and some remaining analyst support. While concerns about cash burn and profitability persist, the potential for biomarker-driven development and the insider conviction suggest a stable, albeit cautious, outlook.

• Alumis (ALMS) news sentiment is neutral, driven by a mixed Phase 2b lupus trial outcome where a positive subgroup response contrasts with overall endpoint misses, alongside significant insider buying and analyst support, but tempered by a substantial stock...
• Alumis (ALMS) sentiment is neutral, balancing positive insider buying and pipeline potential against the recent failure of its Phase 2b LUMUS trial in the overall population and significant stock volatility. (Score: 0.0)
• Alumis faces significant headwinds following a Phase 2b trial miss for its lead asset, leading to substantial stock price declines and analyst downgrades, though a specific patient subgroup's positive response and insider buying offer some potential...

Risk team: High

ALMS presents a HIGH risk profile due to a recent clinical trial failure, extreme volatility, and significant cash burn. The company's reliance on a single collaboration partner and the inherent binary nature of biotech drug development amplify these risks. Consequently, a SMALL position size with aggressive risk management is recommended.

• Clinical Trial Failure: The company's primary asset, envudeucitinib, recently failed to meet endpoints in a Phase 2b lupus trial, underscoring the high risk of drug development failure.
• Extreme Realized Volatility: The annualized realized volatility is extremely high at 212.96% (20d), indicating significant price swings and potential for substantial losses.
• Deep 1-Year Drawdown: The stock has experienced a maximum drawdown of -78.95% over the past year, signifying substantial downside risk.

ALMS at a glance

Market value	$822.7M
Revenue growth (year over year)	-69.2%
Profit margin	-5933.5%
Debt / equity	0.00

Every AI call on ALMS since June 23, 2026, and what happened next (5 calls) →

Research of September 10, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.